GlassScriptPhysician profile
Suhail Mohiuddin
NPI 1316258544
$950.32
in general payments reported to CMS, 2019-2025
4 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $180 · 2023: $450 · 2024: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550 · Gift: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.20 |
| Gift | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Align Technology, INC. | $736.89 | 2019-2023 | Itero Element 5d Plus, Itero Element 5d Plus Lite, Vivera Retainers |
| Orapharma, A Division of Bausch Health US, LLC | $100.51 | 2024 | Arestin |
| Henry Schein, INC. | $100.00 | 2024 | |
| Kulzer, LLC | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suhail Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.